The DOI matches its Crossref record.
Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study
Open accessAbstract
Objective: To investigate longitudinal changes in the liver stiffness measurement (LSM) in the general adult population without known liver disease and to describe its association with metabolic risk factors, with a special focus on subjects with non-alcoholic fatty liver disease (NAFLD) and dysglycemia. Material and Methods: A longitudinal adult population-based cohort study was conducted in Catalonia. LSM was measured by transient elastography (TE) at baseline and follow-up (median: 4.2 years). Subgroup with NAFLD and dysglycemia were analyzed. Moderate-to-advanced liver fibrosis was defined as LSM ≥8.0 kPa and LSM ≥9.2 kPa respectively. Results: Among 1.478 subjects evaluated, the cumulative incidence of LSM ≥8.0 kPa and ≥9.2 kPa at follow-up was 2.8% and 1.9%, respectively. This incidence was higher in NAFLD (7.1% for LSM ≥8.0 kPa and 5% for LSM ≥9.2 kPa) and dysglycemia (6.2% for LSM ≥8.0 kPa and 4.7% for LSM ≥9.2 kPa) subgroups. In the global cohort, the multivariate analyses showed that dysglycemia, abdominal obesity and atherogenic dyslipidemia were significantly associated with progression to moderate-to-advanced liver fibrosis. Female sex was negatively associated. In subjects with NAFLD, abdominal obesity and dysglycemia were associated with changes in LSM to ≥8.0 kPa and ≥9.2 kPa at follow-up. A decline in LSM value to <8 kPa was observed in 64% of those subjects with a baseline LSM ≥8.0 kPa. Conclusions: In this population study, the presence of abdominal obesity and dysglycemia were the main risk metabolic factors associated with moderate-to-advanced liver fibrosis development over time in general populations as well as in subjects with NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The incidence of moderate-to-advanced liver fibrosis was higher in MASLD (7.1% for LSM >8.0 kPa and 5% for LSM >9.2 kPa) and dysglycaemia (6.2% for LSM >8.0 kPa and 4.7% for LSM >9.2 kPa) subgroups.
“This incidence was higher in MASLD (7.1% for liver stiffness measurement [LSM] > -8.0 kPa and 5% for LSM > -9.2 kPa) and dysglycaemia (6.2% for LSM > -8.0 kPa and 4.7% for LSM > -9.2 kPa) subgroups.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [63]
The Results sections on NAFLD and dysglycemia report the four stated incidence percentages. However, the paper measured the NAFLD subgroup, not a subgroup defined as MASLD, and used LSM ≥8.0 and ≥9.2 kPa rather than the claim’s strict > thresholds. No page numbers are available in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measuredIn a population-based study, the cumulative incidence of moderate-to-advanced liver fibrosis estimated by VCTE was 2.8% and 1.9% over a median period of around 4 years.
“In a population-based study, 63 the cumulative incidence of moderate-to-advanced liver fi brosis estimated by VCTE was 2.8% and 1.9%, respectively, over a median period of around 4 years.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [63]
In the global cohort, dysglycaemia, abdominal obesity and atherogenic dyslipidaemia were independent determinants of progression to moderate-to-advanced liver fibrosis.
“In the global cohort, dysglycaemia, abdominal obesity and atherogenic dyslipidaemia were independent determinants of progression to moderate-to-advanced liver fi brosis.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 24
- Bazerbachi, 2019, Range of normal liver stiffness and factors associated with increased stiffness measurements in apparently healthy individuals, Clin Gastroenterol Hepatol, 17, 54, 10.1016/j.cgh.2018.11.017 · DOI
- Roulot, 2008, Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome, J Hepatol, 48, 10.1016/j.jhep.2007.11.020 · DOI
- Koehler, 2016, Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study, Hepatology., 63, 10.1002/hep.27981 · DOI
- Petta, 2018, Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population, Liver Int, 38, 10.1111/liv.13743 · DOI
- Caballería, 2018, High prevalence of liver fibrosis among European adults with unknown liver disease: A population-based study, Clin Gastroenterol Hepatol [Internet], 16, 1138, 10.1016/j.cgh.2017.12.048 · DOI
- Julián, 2021, Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: A population-based study, Eur J Endocrinol, 184, 10.1530/EJE-20-1240 · DOI
- Kim, 2014, Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis b receiving entecavir, Liver Int, 34, 10.1111/liv.12377 · DOI
- Lallukka, 2017, Predictors of liver fat and stiffness in non-alcoholic fatty liver disease (NAFLD) - an 11-year prospective study, Sci Rep, 7, 1, 10.1038/s41598-017-14706-0 · DOI
- Fung, 2011, Significant changes in liver stiffness measurements in patients with chronic hepatitis b: 3-year follow-up study, J Viral Hepat, 18, 10.1111/j.1365-2893.2010.01428.x · DOI
- Bedogni, 2006, The fatty liver index: A simple and accurate predictor of hepatic steatosis in the general population, BMC Gastroenterol, 6, 1, 10.1186/1471-230X-6-33 · DOI
- Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases, Hepatology., 67, 10.1002/hep.29367 · DOI · Paper page
- Castera, 2019, Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease, Gastroenterol [Internet], 156, 1264, 10.1053/j.gastro.2018.12.036 · DOI · Paper page
- Eddowes, 2019, Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease, Gastroenterol [Internet], 156, 10.1053/j.gastro.2019.01.042 · DOI
- Mikolasevic, 2020, Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements, J Diabetes Complications [Internet], 34, 10.1016/j.jdiacomp.2019.107512 · DOI
- Stefan, 2022, A global view of the interplay between non-alcoholic fatty liver disease and diabetes, Lancet Diabetes Endocrinol, 10, 10.1016/S2213-8587(22)00003-1 · DOI · Paper page
- Barb, 2021, Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease, Obesity., 29, 10.1002/oby.23263 · DOI
- Ciardullo, 2021, High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes, Diabetes Care, 44, 10.2337/dc20-1778 · DOI
- Lomonaco, 2021, Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: The need for systematic screening, Diabetes Care, 44, 399, 10.2337/dc20-1997 · DOI · Paper page
- Portillo-Sanchez, 2015, High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels, J Clin Endocrinol Metab, 100, 10.1210/jc.2015-1966 · DOI · Paper page
- Unalp-Arida, 2021, Transient elastography assessed hepatic steatosis and fibrosis are associated with body composition in the united states, Clin Gastroenterol Hepatol, 5, 10.1016/j.cgh.2021.02.009 · DOI
- Kwok, 2016, Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: A prospective cohort study, Gut., 65, 10.1136/gutjnl-2015-309265 · DOI
- Ballestri, 2017, NAFLD as a sexual dimorphic disease: Role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk, Adv Ther, 34, 10.1007/s12325-017-0556-1 · DOI
- Ginès, 2016, Screening for liver fibrosis in the general population: a call for action, Lancet Gastroenterol Hepatol [Internet], 1, 10.1016/S2468-1253(16)30081-4 · DOI
- Romero-Gómez, 2017, Treatment of NAFLD with diet, physical activity and exercise, J Hepatol, 67, 10.1016/j.jhep.2017.05.016 · DOI · Paper page
Cited by
Sorted by citations
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Metadata
- Authors
- Julián, M. T., Ballesta, S., Pera, G., Pérez-Montes de Oca, A., Soldevila, B., Caballería, L., Morillas, R., Expósito, C., Martínez–Escudé, A., Puig-Domingo, M., Franch-Nadal, J., Torán, P., Cusi, K., Julve, J., Mauricio, D., & Alonso, N.
- Affiliations
- Hospital Universitari Germans Trias i Pujol (ES)
- Institut Universitari d'Investigació en Atenció Primària Jordi Gol (ES)
- Universitat Autònoma de Barcelona (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- University of Florida Health (US)
- Corresponding author
- Alonso, Núria
- ORCID
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2023-01-13
- Volume
- 13
- Pages
- 1051958-1051958
- ISSN
- 1664-2392 (ISSN-L)
- PMC
- PMC9880071
- OpenAlex
- W4315782495
- Cited by
- 30
- References
- 0
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 12 · 2023: 2
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Instituto de Salud Carlos III (PI21/00817)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- non-alcoholic fatty liver disease, liver fibrosis progression, abdominal obesity, dysglycemia, liver stiffness measurement, transient elastography, atherogenic dyslipidemia, metabolic risk factors, sex differences, general adult population
- MeSH terms
- Adult, Female, Humans, Liver Cirrhosis, Obesity, Risk Factors, Cohort Studies, Obesity, Abdominal, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
